Effects of Two Asthma Inhalers on Lung Airflow and Blood Flow in Adults
Tests albuterol and albuterol-budesonide inhalers on lung airflow in adults with asthma.
Plain-language title generated from the registry record
Registry title: Ventilation and Perfusion in Asthmatics
Key facts
- Where
- Miami, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07426458, who can take part
Where in United States
- University of Miami - Converge MiamiMiami, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Miami
- Trial code
- NCT07426458
- Record updated
- 23 October 2026
- Original description
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).Read full original descriptionShow less
Ventilation and Perfusion in Individuals With Asthma
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).
Inclusion: Physician diagnosis of asthma; Baseline Forced Expiratory Volume in 1 Second (FEV1) < 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry; Adults, 18-75 years of age; Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment.
Exclusion: Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance; Current cigarette smoking or a past history of >10 pack-year smoking; Respiratory infection within 4 weeks of proposed study date; Current nicotine vaping; Pregnant and breast-feeding women; Forced Expiratory Volume in 1 Second (FEV1) < 50%; Use of beta-blockers; Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.